Review demonstrates key economic and technical barriers in one-carbon biomanufacturing, highlighting a viable roadmap for scalable, cost-competitive carbon neutrality.
One-carbon (C1) biomanufacturing serves as a substitute for fossil-based feedstocks, aiming to de-fossilize chemical production and foster a circular carbon economy by recycling waste greenhouse gases. Here, we review the key economic and technical barriers associated with the commercialization of C1 biomanufacturing through case studies. Additionally, a viable roadmap to enhance cost competitiveness is unveiled, underscoring its potential to facilitate carbon neutrality as scalable and sustainable alternatives to traditional chemical production.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: